Industry / United Kingdom
GSK Announces Mixed Results
February 2008 | Industry NewsUK-based drugmaker GlaxoSmithKline has announced that turnover fell marginally in 2007, to US$22.7bn (US$44.3bn) after safety warnings had an impact on sales of its leading diabetes drug Avandia (rosiglitazone) and generic competition reduced sales in the key US market.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
